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MaBACKGROUND Recent studies from Asia have suggested that the risk of ischemic stroke for patients with atrial
ﬁbrillation (AF) with a “low-risk” congestive heart failure, hypertension, age $75, diabetes mellitus, prior stroke or
transient ischemic attack, vascular disease, age 65 to 74, female (CHA2DS2-VASc) score of 0 (for males) or 1 (for females)
might be higher than that for non-Asians.
OBJECTIVES This study hypothesized that the age threshold (65 years) used in the CHA2DS2-VASc system for initiating
oral anticoagulants (OACs) might be lower in Taiwanese AF patients than in non-Asians.
METHODS We used the National Health Insurance Research Database in Taiwan to study 186,570 nonanticoagulated AF
patients. There were 9,416 males with a CHA2DS2-VASc score of 0 and 6,390 females with a CHA2DS2-VASc score of 1.
Their risk of ischemic stroke was analyzed with stratiﬁcation on the basis of age.
RESULTS The annual risks of ischemic stroke for males (score 0) and females (score 1) were 1.15% and 1.12%,
respectively, and continuously increased from younger to older age groups, with an increment in stroke risk evident for
patients >50 years of age. At a cutoff of 50 years, patients could be further stratiﬁed into 2 subgroups with different
stroke risks (>50 years of age: 1.78%/year; vs. <50 years of age: 0.53%/year). This observation was consistent for males
(1.95%/year vs. 0.46%/year, respectively) and females (1.58%/year vs. 0.64%/year, respectively) with AF. In a subgroup
analysis, the annual risks of ischemic stroke for males and females with AF 50 to 54 years of age were 1.47% and 1.07%,
respectively.
CONCLUSIONS For Taiwanese patients 50 to 64 years of age, the annual stroke risk was 1.78%, which may exceed the
threshold for OAC use for stroke prevention. The annual risk of ischemic stroke for AF patients <50 years of age was
0.53%, which was truly low-risk, and OACs could be omitted. Whether resetting the age threshold to 50 years could
reﬁne current clinical risk stratiﬁcation for Asian AF patients deserves further study. (J Am Coll Cardiol 2015;66:1339–47)
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CI = conﬁdence interval
ESC = European Society of
Cardiology
ICD-9-CM = International
Classiﬁcation of Diseases-Ninth
Revision-Clinical Modiﬁcation
NHI = National Health
Insurance
NHIRD = National Health
Insurance Research Database
NOACs = non-vitamin K
antagonist oral anticoagulants
OACs = oral anticoagulants
ROC curve = receiver
operating characteristic curve
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1340A trial ﬁbrillation (AF) is the most com-mon, sustained cardiac arrhythmiaand increases the risk of ischemic
stroke by 4- to 5-fold (1). The risk of AF-
associated stroke is not homogeneous and
depends on the patient’s age and comorbid-
ities. This has resulted in clinical scores to
aid risk stratiﬁcation for patients with AF.SEE PAGE 1348The CHA2DS2-VASc score (congestive heart
failure, hypertension, age$75, diabetesmelli-
tus, prior stroke or transient ischemic attack,
vascular disease, age 65 to 74, female) has
been validated as useful for stroke risk predic-
tion in several independent cohorts (2–7), and
current European and American guidelinesrecommenduse of the CHA2DS2-VASc scheme to assess
stroke risk (8,9). Compared to the CHADS2 system
(congestive heart failure, hypertension, age $75, dia-
betes mellitus, and prior stroke or transient ischemic
attack), previous studies have demonstrated that the
CHA2DS2-VASc score reliably identiﬁes “truly low-
risk” patients, even among those with a low CHADS2
score (4,5). In the Danish nationwide cohort study,
the annual risk of ischemic stroke was 0.66% for male
patients with a CHA2DS2-VASc score of 0 and 0.82%
for female patients with a CHA2DS2-VASc score of 1
(2). A low risk of ischemic stroke for male patients
with AF and a CHA2DS2-VASc score of 0 was also
evident in Swedish (0.2% risk per year) and American
(0.04% risk per year) cohorts (10,11). Given the low
risk of ischemic stroke, current major guidelines sug-
gest that oral anticoagulants (OACs) could be omitted
for males with AF and a CHA2DS2-VASc score of 0 and
for females with AF and a score of 1 (8,9).
What is the risk of ischemic stroke for these “low-
risk” patients in Asia? In a previous nationwide study
from Taiwan, the annual risk of ischemic stroke was
1.15% for male AF patients with a CHA2DS2-VASc score
of 0,whichwas higher than that reported fromWestern
countries (12). In the recent study by Siu et al. (13),
which enrolled 9,727 Hong Kong AF patients from a
hospitalized cohort, the annual stroke rate was as high
as 2.41% among 395 patients with a CHA2DS2-VASc
score of 0 (13). Thus, stroke risk among Asian patients
with AF and a CHA2DS2-VASc score of 0 (males) or 1
(females) might be higher than that seen among Cau-
casians, and such patients may still require OACs for
effective stroke prevention because the threshold for
initiating anticoagulation can be lowered to a stroke
rate of 0.9%/year with the better safety proﬁle of non-
vitamin K antagonist OACs (NOACs) (14).By its current deﬁnition, the CHA2DS2-VASc score
assigns 1 point for patients older than 65 years of age,
although the setting of the threshold for age has not
been previously well studied for Asians. In the pre-
sent study, we aimed to investigate the risk of
ischemic stroke in male patients with a CHA2DS2-
VASc score of 0 and female patients with a CHA2DS2-
VASc score of 1 stratiﬁed on the basis of age. We
hypothesized that the threshold age (65 years) used in
the CHA2DS2-VASc system might have to be lowered
in Taiwanese AF patients.
METHODS
DATABASE. This study used the National Health In-
surance Research Database (NHIRD) released by the
Taiwan National Health Research Institutes. The Na-
tional Health Insurance (NHI) system is a mandatory
universal health insurance program that offers com-
prehensive medical care coverage to all Taiwanese
residents. NHIRD consists of detailed health care data
from >23 million enrollees, representing >99% of
Taiwan’s population. In this cohort dataset, patients’
original identiﬁcation numbers were encrypted to
protect patients’ privacy, but the encrypting proce-
dure was consistent, so that a linkage of claims
belonging to the same patient was feasible within the
NHI database and could be followed continuously. The
large sample size of this database provided a good
opportunity to study the risk of ischemic stroke in
“low-risk” patients with AF and a CHA2DS2-VASc score
of 0 (for males) and 1 (for females), stratiﬁed by age.
STUDY COHORT. The study protocol for the present
study was similar to that of our previous studies
(12,15). From January 1, 1996, to December 31, 2011, a
total of 354,649 AF patients $20 years of age were
identiﬁed from the NHIRD as the study population.
AF was diagnosed using International Classiﬁca-
tion of Diseases-Ninth Revision-Clinical Modiﬁcation
(ICD-9-CM) code 427.31. To ensure accuracy of diag-
nosis, we deﬁned patients with AF only when it was a
discharge diagnosis or was conﬁrmed more than
twice in the outpatient department (12,15,16). Diag-
nostic accuracy of AF using this deﬁnition in NHIRD
has been validated previously (17,18). The CHA2DS2-
VASc score was calculated for each patient by
assigning 1 point each for age between 65 and 74
years, history of hypertension, diabetes, recent car-
diac failure, vascular disease (myocardial infarction
or peripheral artery disease), and female sex, and 2
points each for a history of a stroke, transient
ischemic attack, or $75 years of age (19). From the
study population, we excluded patients who received
treatments with warfarin or any antiplatelet agent,
FIGURE 1 Flowchart of the Enrollment of the Study Cohort
NHIRD cohort (1996–2011)
More than 23 million enrollees
AF patients older than 20 years
(n = 354,649)
AF patients without use of any anti-
platelet or anticoagulant agent
(n = 186,570)
AF patients with a CHA2DS2-VASc
score of 0 (males) or 1 (females)
(n = 15,806)
AF males with a CHA2DS2-
VASc score of 0
(n = 9,416)
AF females with a CHA2DS2-
VASc score of 1
(n = 6,390)
Among 186,570 AF patients who were not receiving oral anticoagulants or antiplatelet
agents, there were 9,416 males with a CHA2DS2-VASc score of 0 and 6,390 females with a
CHA2DS2-VASc score of 1. Their risk of ischemic stroke was analyzed and further stratiﬁed
on the basis of age. AF ¼ atrial ﬁbrillation; CHA2DS2-VASc ¼ congestive heart failure,
hypertension, age $75, diabetes mellitus, prior stroke or transient ischemic attack,
vascular disease, age 65 to 74, female.
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1341including aspirin, clopidogrel, dipyridamole, and
ticlopidine. Finally, a total of 186,570 patients were
enrolled in the study cohort, with 15,806 patients
having a CHA2DS2-VASc score of 0 (males [n ¼ 9,416])
or 1 (females [n ¼ 6,390]). A ﬂowchart of the study
cohort is shown in Figure 1.
DEFINITION OF CLINICAL ENDPOINT. The clinical
endpoint was occurrence of ischemic stroke, with
concomitant imaging studies of the brain, including
computed tomography or magnetic resonance imag-
ing. The accuracy of diagnosis of ischemic stroke in
Taiwan’s NHIRD has been reported to be approxi-
mately 94% (20). Another validation study also
demonstrated that the diagnostic accuracy of ischemic
stroke in NHIRD was high, with a positive predictive
value of 88.4% and a sensitivity value of 97.3% (21).
The annual risk of ischemic stroke was calculated
for patients who were stratiﬁed into 5 groups on the
basis of age (20 to 29 years, 30 to 39 years, 40 to
49 years, 50 to 59 years, and 60 to 64 years).
STATISTICAL ANALYSIS. Data are presented as
mean  SD for normally distributed continuous vari-
ables and as proportions for categorical variables. The
unpaired 2-tailed Student t test was used for analysis
of continuous variables, and the differences between
nominal variables were compared by chi-square test.
Incidence rates of ischemic stroke were calculated by
dividing the number of events by person-time at risk,
with the 95% conﬁdence interval (CI) estimated by
exact binomial probabilities. The cumulative inci-
dence curve of ischemic stroke was plotted via the
Kaplan-Meier method, with statistical signiﬁcance
examined by the log-rank test. The risk of ischemic
stroke was assessed using Cox regression analysis. We
assessed the predictive accuracy of age for ischemic
stroke by calculating the c-index on the basis of the
receiver operating characteristic (ROC) curve. The
cutoff age value in the prediction of ischemic stroke
was deﬁned as the cutoff point having the highest
Youden index (sensitivity þ speciﬁcity  1) (22). Sta-
tistical signiﬁcance was set at a p value of <0.05.
RESULTS
ANNUAL RISK OF ISCHEMIC STROKE OF PATIENTS
STRATIFIED ON THE BASIS OF AGE. The mean  SD
ages were 47.5  11.8 years for males, 48.4  11.0 years
for females, and 47.9  11.5 years for all patients. The
annual risks of ischemic stroke for males (score 0), fe-
males (score 1), and the whole cohort were 1.15%,
1.12%, and 1.14%, respectively. Table 1 shows the
annual stroke risk stratiﬁed by age for males, females,
and all patients. The risk of ischemic stroke continu-
ously increased from younger to older age groups, andthe increment risk of stroke risk was particularly
evident for patients older than 50 years of age.
The cumulative incidence curve using the log-rank
test shows that patients in older age groups were
associated with a higher risk of ischemic stroke dur-
ing the follow-up period (Figure 2). The relative risk of
ischemic stroke for AF patients with a CHA2DS2-VASc
score of 0 (males) or 1 (females) in different age
groups compared with patients between 20 and
39 years of age was expressed using hazard ratios,
which continuously increased from younger to older
age group strata (Figure 3).
CUTOFF VALUE OF AGE FOR THE PREDICTION OF
ISCHEMIC STROKE. Figure 4 shows the ROC curve on
the basis of age for the prediction of ischemic stroke.
The c-index for age was 0.69 (95% CI: 0.67 to 0.70),
and the cutoff value for age (50 years) was identiﬁed
on the basis of the highest Youden index (Figure 4).
The sensitivity, speciﬁcity, and Youden index in
predicting ischemic stroke for different cutoff values
of age are shown in Table 2.
TABLE 1 Risk of Ischemic Stroke in AF patients With a CHA2DS2-VASc Score
of 0 (Male) or 1 (Female) Stratiﬁed by Age
Age, yrs n
Number of
Events Person-Years
% of Annual Stroke Rate
(95% CI)
Males
20–29 939 4 6,029 0.07 (0.02–0.17)
30–39 1,423 40 9,497 0.42 (0.30–0.57)
40–49 2,438 101 16,075 0.63 (0.51–0.76)
50–54 1,382 125 8,514 1.47 (1.22–1.75)
55–59 1,526 146 9,106 1.60 (1.35–1.89)
60–64 1,708 267 10,012 2.67 (2.36–3.01)
Total 9,416 683 59,233 1.15 (1.07–1.24)
Females
20–29 478 6 3,354 0.18 (0.07–0.39)
30–39 877 29 6,103 0.48 (0.32–0.68)
40–49 1,705 101 11,739 0.86 (0.70–1.05)
50–54 1,091 75 6,986 1.07 (0.84–1.35)
55–59 1,100 108 7,232 1.49 (1.23–1.80)
60–64 1,139 165 7,838 2.11 (1.80–2.45)
Total 6,390 484 43,252 1.12 (1.02–1.23)
All patients
20–29 1,417 10 9,383 0.11 (0.05–0.20)
30–39 2,300 69 15,600 0.44 (0.34–0.56)
40–49 4,143 202 27,814 0.73 (0.63–0.83)
50–54 2,473 200 15,500 1.29 (1.12–1.48)
55–59 2,626 254 16,338 1.56 (1.37–1.76)
60–64 2,847 432 17,850 2.42 (2.20–2.66)
Total 15,806 1,167 102,485 1.14 (1.07–1.21)
AF ¼ atrial ﬁbrillation; CHA2DS2-VASc¼ congestive heart failure, hypertension, age$75, diabetes
mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 74, female;
CI ¼ conﬁdence interval.
FIGURE 2 Cumulative Incidence Curves for Ischemic Stroke in Different Age Groups
Log-rank test p < 0.001
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The cumulative incidence curve with the log-rank test demonstrated that patients in the
older age group were associated with a higher risk of ischemic stroke during the follow-up
period than younger patients.
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1342Among study patients with a CHA2DS2-VASc score
of 0 (males) or 1 (females), the annual stroke rate was
1.14%. These patients could be further stratiﬁed into 2
subgroups with different risks of stroke (age $50,
1.78% per year vs. younger [age <50], 0.53% per year)
on the basis of the cutoff value of age set at 50 years
(Central Illustration). The ﬁnding was consistently
observed for males (1.95% per year vs. 0.46% per
year, respectively) and females (1.58% per year vs.
0.64% per year, respectively). In a subgroup analysis,
the annual risks of ischemic stroke for males and
females with AF, 50 to 54 years of age, were 1.47%
and 1.07%, respectively.
DISCUSSION
In this nationwide study using a large “real-world”
cohort of nonanticoagulated Taiwanese AF patients,
we demonstrated that resetting the age threshold at
50 years may be able to further identify truly low-risk
patients with AF among males with a CHA2DS2-VASc
score of 0 and females with a CHA2DS2-VASc score of
1. The annual risk of ischemic stroke was as low as
0.46% for males and 0.64% for females who were
younger than 50 years and did not have any risk
factors on the basis of CHA2DS2-VASc score.
DIFFERENCES IN RISK OF ISCHEMIC STROKE
BETWEEN ASIANS AND NON-ASIANS. Recently,
2 large-scale cohort studies from Taiwan and Hong
Kong reported the incidence of ischemic stroke for
Asian AF patients in relation to the CHA2DS2-VASc
score (12,13). The annual stroke risks for patients with
a CHA2DS2-VASc score of 0 were 1.15% and 2.41% in
the Taiwan and Hong Kong cohorts, respectively
(12,13). These reported stroke risks for Asians were
higher than those of other registry studies that mainly
enrolled Caucasians, which ranged from 0.04% to
0.66% per year (2,10,11,23,24).
The consistently higher risk of ischemic stroke in
Asians than in non-Asians was also noted in patients
who received NOACs in randomized trials (25). In the
RE-LY (Randomized Evaluation of Long-Term Anti-
coagulation Therapy) trial, there were 2,782 patients
from Asian countries, representing 15% of the trial
cohort (26). The risks of ischemic stroke in Asians in
the dabigatran arm were higher than those of non-
Asians (2.05%/year vs. 1.14%/year for dabigatran,
110 mg twice daily by mouth; and 1.12%/year vs.
0.81%/year for dabigatran, 150 mg by mouth) (27). In
ROCKET-AF (Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation), there were 932 patients
from East Asian countries (28). Despite a younger
FIGURE 3 Risk of Ischemic Stroke for AF Patients With a CHA2DS2-VASc Score of 0 (Males) or 1 (Females) Stratiﬁed on the Basis of Age
AF MALES
Hazard ratio* (95% CI)
0.8 1.0 3.0 6.0 9.0 12.0
Hazard ratio* (95% CI)
Age 20—39
(reference group) 1
Age 40—49
Age 50—54
Age 55—59
Age 60—64
2.207 (1.549—3.145)
5.199 (3.688—7.330)
5.616 (4.009—7.867)
9.358 (6.803—12.872)
AF FEMALES
Hazard ratio* (95% CI)
0.8 1.0 3.0 6.0 9.0 12.0
Hazard ratio* (95% CI)
Age 20—39
(reference group) 1
Age 40—49
Age 50—54
Age 55—59
Age 60—64
2.317 (1.578—3.403)
2.933 (1.964—4.380)
4.029 (2.752—5.899)
5.650 (3.923—8.136)
ALL PATIENTS
Hazard ratio* (95% CI)
0.8 1.0 3.0 6.0 9.0 12.0
Hazard ratio* (95% CI)
Age 20—39
(reference group) 1
Age 40—49
Age 50—54
Age 55—59
Age 60—64
2.287 (1.764—2.967)
4.105 (3.164—5.326)
4.891 (3.800—6.296)
7.598 (5.978—9.657)
The hazard ratios of ischemic stroke continuously increased from younger to older age groups. *The risk of ischemic stroke was compared with
that of AF patients between 20 and 39 years of age. CI ¼ conﬁdence interval; other abbreviations as in Figure 1.
J A C C V O L . 6 6 , N O . 1 2 , 2 0 1 5 Chao et al.
S E P T E M B E R 2 2 , 2 0 1 5 : 1 3 3 9 – 4 7 Age Threshold for Taiwanese AF Patients
1343mean age (69.6 years vs. 71.3 years) and lower mean
CHA2DS2-VASc score (4.4 vs. 4.9) in Asians than in
non-Asians, the risk of ischemic stroke was higher in
East Asians than in non-Asians under rivaroxaban
treatment (2.12%/year vs. 1.59%/year, respectively)
(29). Last, in the ARISTOTLE (Apixaban for Reduction
in Stroke and Other Thromboembolic Events in Atrial
Fibrillation) trial, there were 1,993 patients from
Asian countries (30). The mean CHA2DS2-VASc scorewas 3.3 for Asians and 3.4 for non-Asians. In the
apixaban arm, the risk of ischemic stroke in Asians
was higher than that in non-Asians (2.22%/year vs.
0.82%/year, respectively) (31). The risk of ischemic
stroke in Asians was also consistently higher than
that of non-Asians in the warfarin arms of these ran-
domized trials (2.02%/year vs. 0.98%/year, respec-
tively, in RE-LY; 2.24%/year vs. 1.60%/year,
respectively, in ROCKET-AF; and 1.90%/year vs.
FIGURE 4 ROC Curve of Age in Predicting Ischemic Stroke
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The c-index on the basis of the AUC for age in predicting ischemic stroke was 0.69. The
cutoff value of age (50 years) was identiﬁed on the basis of the highest Youden’s index.
AUC ¼ area under the curve; ROC ¼ receiver operating characteristic.
TABLE 2 Sensitivity and Speciﬁcity in Predicting Ischemic Stroke
on the Basis of Different Cutoff Values of Age
Cutoff Value of Age, yrs Sensitivity Speciﬁcity Youden’s Index*
$40 0.9220 0.2686 0.1906
$41 0.9083 0.2917 0.2000
$42 0.8937 0.3164 0.2101
$43 0.8757 0.3420 0.2177
$44 0.8595 0.3685 0.2280
$45 0.8483 0.3976 0.2459
$46 0.8320 0.4252 0.2572
$47 0.8072 0.4556 0.2628
$48 0.7789 0.4841 0.2630
$49 0.7592 0.5177 0.2769
$50 0.7344 0.5487 0.2831
$51 0.7001 0.5798 0.2799
$52 0.6701 0.6120 0.2821
$53 0.6315 0.6413 0.2728
$54 0.5878 0.6730 0.2608
$55 0.5441 0.7052 0.2493
$56 0.5133 0.7376 0.2509
$57 0.4687 0.7705 0.2392
$58 0.4276 0.8012 0.2288
$59 0.3702 0.8350 0.2052
$60 0.3068 0.8653 0.1721
$61 0.2365 0.8988 0.1353
$62 0.1637 0.9317 0.0954
$63 0.0891 0.9662 0.0553
$64 0.0437 0.9839 0.0276
*Youden’s index ¼ [Sensitivity þ Speciﬁcity  1].
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13440.95%/year, respectively, in ARISTOTLE) (27,29,31).
On the basis of data from the studies mentioned
earlier, the risk of ischemic stroke seems much
higher in Asians than in non-Asians, both for non-
anticoagulated patients in the registry studies and for
anticoagulated patients in the randomized trials.
Why was the risk of ischemic stroke higher in Asians
than in non-Asians? In the present study, we demon-
strated that Taiwanese AF patients started to experi-
ence ischemic stroke at a younger age than non-Asians.
Because age is an important driver of stroke risk, this
may provide an explanation for the observed higher
risk of stroke in Asians than in non-Asians, given the
similar ages and clinical risk scores in previous studies.
However, the detailed mechanism(s) behind the
higher risk of ischemic stroke for younger AF patients
in Taiwanese patients remains unknown and requires
further investigation in prospective studies.
In the present study, which enrolled Taiwanese AF
patients younger than 65 years of age without sig-
niﬁcant comorbidities, on the basis of the deﬁnition
of the CHA2DS2-VASc score, the 95% CIs of the risks of
ischemic stroke for males and females in each age
stratum overlapped. These results may suggest that
female sex alone is not a risk factor of ischemic stroke
in this particular patient population.CLINICAL IMPLICATIONS. Treatments with vitamin
K antagonists, such as warfarin, could effectively
reduce the risk of AF-related stroke by 64% and all-
cause mortality by 26% compared with placebo (32).
However, the underuse of warfarin and poor quality
of anticoagulation control (as reﬂected by time in
therapeutic range [TTR]) for those treated with
vitamin K antagonists are common in Asia, with im-
plications for efﬁcacy and safety while taking
warfarin (33,34). In recent years, several NOACs were
demonstrated to be at least as effective as warfarin in
stroke prevention and were much safer in terms of risk
of intracranial hemorrhage (26,28,30,35). Improve-
ments in convenience and safety of NOACs compared
with warfarin have lowered the threshold for initi-
ating OACs for AF patients. The study performed by
Eckman et al. (14) used a decision analytic model that
analyzed the “tipping point” of OAC for stroke pre-
vention to delineate the threshold of ischemic stroke
risk below which anticoagulant therapy should be
withheld and above which anticoagulant therapy
should be prescribed. That study showed that anti-
coagulation with warfarin is preferred at a stroke
rate above 1.7% per year, whereas anticoagulation
CENTRAL ILLUSTRATION Age Thresholds for Taiwanese AF Patients: A Flowchart Demonstrating Stroke Rates in
Patients Younger and Older Than 50 Years of Age
         >50
(50-64 Years)
                     Males
                (n = 4,616)
       Annual Stroke Rate %
                   = 1.95  
                  Females
               (n = 3,330)
       Annual Stroke Rate %
                  = 1.58  
                  Females
               (n = 3,060)
       Annual Stroke Rate %
                   = 0.64  
                    Males
               (n = 4,800)
       Annual Stroke Rate %
                    = 0.46  
<50
p <0.001
Age
                      n = 7,946 
     Annual Stroke Rate % = 1.78  
                      n = 7,860 
     Annual Stroke Rate % = 0.53  
    Annual Stroke Rate % = 1.14  
     CHA2DS2-VASc Score 
= 0 (Males) or 1 (Females)
           Age <64 Years
              n = 15,806
Chao, T.-F. et al. J Am Coll Cardiol. 2015; 66(12):1339–47.
Among AF patients with a CHA2DS2-VASc score of 0 (males) or 1 (females), the annual stroke rate was 1.14%. These patients can be further
stratiﬁed into 2 groups with different risks of stroke (1.78%/year vs. 0.53%/year) by setting the cutoff value of age at 50 years. AF ¼ atrial
ﬁbrillation; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75, diabetes mellitus, prior stroke or transient ischemic attack,
vascular disease, age 65 to 74, female.
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1345with “safer” NOACs lowers the threshold for anti-
coagulation to a stroke rate of 0.9% per year.
Therefore, the role of modern risk scoring schemes
has shifted to initially identify patients with a truly low
risk of ischemic stroke in whom OACs are not recom-
mended (36,37). On the basis of this concept, the 2012
updated AF guideline of European Society of Cardiol-
ogy (ESC) recommends that OACs should be prescribed
for all patients with AF, except for those with a
CHA2DS2-VASc score of 0 (males) or 1 (females), a
population which has been well demonstrated to be at
low risk of ischemic stroke in previous studies focused
on Caucasians (8). Similarly, the 2014 American Col-
lege of Cardiology/American Heart Association (ACC/
AHA) AF guideline also recommends that OACs and
aspirin could be omitted for AF patients with a
CHA2DS2-VASc score of 0 (9). In the present study, we
demonstrated that the annual risk of ischemic strokemight be as high as 1.78% for Taiwanese AF patients
with a CHA2DS2-VASc score of 0 (males) or 1 (females)
between 50 and 64 years of age, which exceeds the
threshold for initiation of OACs, especially NOACs. For
patients between 20 and 49 years of age, the annual
risks of ischemic stroke were as low as 0.46% for males
and 0.64% for females, which were similar to those
reported in non-Asian populations using an age
threshold of 65 years. Therefore, resetting the age
threshold to 50 years for stroke risk estimation for
Taiwanese AF patients may help physicians to identify
truly low-risk patients inwhomOACs are not necessary
and let some patients initially assumed to be low-risk
to be offered effective stroke prevention (i.e., OACs)
to reduce the risk of fatal and disabling strokes.
Indeed, in male patients 50 to 54 years of age with
AF, the risk of ischemic stroke was 1.47% (95% CI: 1.22
to 1.75%) per year, which is above the threshold for
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
The annual risk of ischemic stroke among a cohort of
Taiwanese patients with nonvalvular AF, 50 to 64
years of age, with a CHA2DS2VASc score of 0 (males)
or 1 (females) averaged 1.78%, whereas the risk was
0.53% for those <50 years of age.
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: For Taiwanese patients with AF,
it may be reasonable to consider anticoagulant
therapy using an age threshold of 50 years, rather
than 65 years as designated using the CHA2DS2VASc
score, which was derived largely in non-Asian
populations.
TRANSLATIONAL OUTLOOK: Prospective studies
are necessary to investigate the net clinical beneﬁt
of initiating anticoagulation therapy in Taiwanese
patients with AF who have no other stroke risk factors
at 50 years of age, as opposed to withholding
antithrombotic prophylaxis.
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1346using NOACs for stroke prevention. However,
the annual risk of ischemic stroke for females aged 50
to 54 years with AF was approximately 1.07%, just
slightly higher than the “tipping point” for using
NOACs (0.9% per year) (14). Therefore, how to treat
these patients in the “gray zone” should be answered
on the basis of sharing decision making with patients
to discuss the risks and beneﬁts of OACs.
STUDY LIMITATIONS. To our knowledge, our study is
the ﬁrst population-based investigation in Taiwanese
patients to analyze the risk of ischemic stroke in
males with AF without non-anticoagulated therapy
and a CHA2DS2-VASc score of 0 and females with AF
and a CHA2DS2-VASc score of 1, stratiﬁed on the basis
of age. The strength of our study was the use of a
nationwide dataset that enrolled a large sample of
subjects.
However, our study has important limitations.
First, the diagnosis of AF and occurrence of ischemic
stroke were communicated on the basis of diagnostic
codes registered by the physicians responsible
for the treatments of patients; nonetheless, the ac-
curacy of diagnosis of AF and ischemic stroke in
Taiwan’s NHIRD has been previously well validated
(17,18,20,21). Second, we only investigated the risk of
ischemic stroke in different age groups and did not
study whether some other unrecognized risk factors
of stroke were present and could be added to the
CHA2DS2-VASc system. However, the purpose of a
scoring system is to assess the risk conveniently and
easily, and therefore the scoring scheme should be as
simple as possible. Furthermore, our results demon-
strated that resetting the age threshold to 50 years for
patients with a CHA2DS2-VASc of 0 (males) or 1
(females) has already been able to identify truly
low-risk patients who did not require OACs for stroke
prevention. More efforts to try to identify more risk
factors among these patients may not provide more
clinical applications because it would not change the
strategy for antithrombotic therapy. Also, patients
who received warfarin or antiplatelet agents were not
enrolled in the present study. Therefore, we did not
consider bleeding risks and the impact of starting
antiplatelet drugs or OAC in a prospective manner.
Third, the present study only enrolled Taiwanesepatients, and whether the results can be extrapolated
to other Asian populations remains uncertain.
CONCLUSIONS
For Taiwanese patients 50 to 64 years of age, the
annual stroke risk was 1.78%, which may exceed the
threshold forOACuse for strokeprevention. The annual
risk of ischemic stroke for AF patients <50 years of age
was 0.53%, which was truly low risk, and OACs could be
clearly omitted. Whether resetting the age threshold at
50 years could reﬁne current clinical risk stratiﬁcation
for Asian AF patients deserves further study.
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